The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China

Cong Li; Jingqi Wang; Xiaobo Sun; Rui Li; Yanyu Chang; Yuge Wang; Xiaonan Zhong; Allan G. Kermode; Zhifeng Mao; Wei Qiu

doi:10.1016/j.jneuroim.2021.577506

The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China

Cong Li, Jingqi Wang, Xiaobo Sun, Rui Li, Yanyu Chang, Yuge Wang, Xiaonan Zhong, Allan G. Kermode, Zhifeng Mao, Wei Qiu

Centre for Neuromuscular and Neurological Disorders (Perron Institute)

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

In this study, we included 461 NMOSD patients at our hospital from January 2016 to June 2019 and got some results. Eight (1.9%) originally AQP4-IgG-seronegative patients were retested as seropositive. 221 patients (47.9%) did not receive immunosuppressive treatment within 3 month. The adult/child distribution was significantly different (p = 0.001). Thirty-three patients (7.2%) had relapses after drug withdrawal, and fifteen of them had used drugs ≥3 years. The conclusion is that decision to treat with immunosuppression was made less often in children than in adults. Patients who took medication for a long time still need to be cautious of stopping using immunosuppression.

Original language	English
Article number	577506
Journal	Journal of Neuroimmunology
Volume	353
DOIs	https://doi.org/10.1016/j.jneuroim.2021.577506
Publication status	Published - 15 Apr 2021

Access to Document

10.1016/j.jneuroim.2021.577506

Cite this

@article{41ffbb67ad3d4a2995098a7e366f1cb2,

title = "The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China",

abstract = "In this study, we included 461 NMOSD patients at our hospital from January 2016 to June 2019 and got some results. Eight (1.9%) originally AQP4-IgG-seronegative patients were retested as seropositive. 221 patients (47.9%) did not receive immunosuppressive treatment within 3 month. The adult/child distribution was significantly different (p = 0.001). Thirty-three patients (7.2%) had relapses after drug withdrawal, and fifteen of them had used drugs ≥3 years. The conclusion is that decision to treat with immunosuppression was made less often in children than in adults. Patients who took medication for a long time still need to be cautious of stopping using immunosuppression.",

author = "Cong Li and Jingqi Wang and Xiaobo Sun and Rui Li and Yanyu Chang and Yuge Wang and Xiaonan Zhong and Kermode, {Allan G.} and Zhifeng Mao and Wei Qiu",

year = "2021",

month = apr,

day = "15",

doi = "10.1016/j.jneuroim.2021.577506",

language = "English",

volume = "353",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder

T2 - Experience with 461 cases from a single centre in South China

AU - Li, Cong

AU - Wang, Jingqi

AU - Sun, Xiaobo

AU - Li, Rui

AU - Chang, Yanyu

AU - Wang, Yuge

AU - Zhong, Xiaonan

AU - Kermode, Allan G.

AU - Mao, Zhifeng

AU - Qiu, Wei

PY - 2021/4/15

Y1 - 2021/4/15

N2 - In this study, we included 461 NMOSD patients at our hospital from January 2016 to June 2019 and got some results. Eight (1.9%) originally AQP4-IgG-seronegative patients were retested as seropositive. 221 patients (47.9%) did not receive immunosuppressive treatment within 3 month. The adult/child distribution was significantly different (p = 0.001). Thirty-three patients (7.2%) had relapses after drug withdrawal, and fifteen of them had used drugs ≥3 years. The conclusion is that decision to treat with immunosuppression was made less often in children than in adults. Patients who took medication for a long time still need to be cautious of stopping using immunosuppression.

AB - In this study, we included 461 NMOSD patients at our hospital from January 2016 to June 2019 and got some results. Eight (1.9%) originally AQP4-IgG-seronegative patients were retested as seropositive. 221 patients (47.9%) did not receive immunosuppressive treatment within 3 month. The adult/child distribution was significantly different (p = 0.001). Thirty-three patients (7.2%) had relapses after drug withdrawal, and fifteen of them had used drugs ≥3 years. The conclusion is that decision to treat with immunosuppression was made less often in children than in adults. Patients who took medication for a long time still need to be cautious of stopping using immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=85100376184&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2021.577506

DO - 10.1016/j.jneuroim.2021.577506

M3 - Article

C2 - 33549943

AN - SCOPUS:85100376184

SN - 0165-5728

VL - 353

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

M1 - 577506

ER -

The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China

Abstract

Access to Document

Other files and links

Fingerprint

Cite this